2019年《ATS/CDC/ERS/IDSA临床实践指南:耐药结核病治疗》解读及与我国《耐药结核病化学治疗指南(2019年)》对比  

Interpretation of“An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline:Treatment of Drug-Resistant Tuberculosis”and comparison with“Guideline for Chemotherapy of Drug Resistant Tuberculosis(2019)”in China

作　　者：刘一典[1] 桂徐蔚[1] 申晓娜[1] 于媛媛 姚岚[1] 楼海[1] 沙巍[1] 肖和平[1] Yi-dian LIU;Xu-wei GUI;Xiao-na SHEN;Yuan-yuan YU;Lan YAO;Hai LOU;Wei SHA;He-ping XIAO(Tuberculosis Diagnosis Center of Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院结核病临床研究中心,200433

出　　处：《中国防痨杂志》2020年第1期12-16,共5页Chinese Journal of Antituberculosis

摘　　要：作者介绍了《ATS/CDC/ERS/IDSA临床实践指南:耐药结核病治疗》的要点,包括耐药结核病治疗的药品、方案制定及疗程、异烟肼单耐药结核病的治疗、耐多药结核病接触者的治疗等;并与我国《耐药结核病化学治疗指南(2019年)》进行了对比,对于不同之处提出了自己的意见。To interpret the“Treatment of Drug-resistant Tuberculosis.An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline(ATS Guideline)”,including the drugs,formulating treatment regimen and duration,as well as treatment of isoniazid-resistant TB,preventive therapy of close contacts of MDR-TB;and then to compared“ATS Guideline”with“Guideline for Chemotherapy of Drug Resistant Tuberculosis(2019)”in China.

关 键 词：结核 抗多种药物性 药物疗法 联合 方案评价 评论 指南 

分 类 号：R52[医药卫生—内科学]